8-KRegulation FDOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 3, 2019)

Filed January 3, 2019For Securities:BMYCELG-RIBMYMP

Summary

This 8-K filing from Bristol-Myers Squibb (BMY) on January 3, 2019, primarily announces two significant events. Firstly, the company provided its earnings per share guidance for the fiscal year 2019. Secondly, and more importantly for investors, BMY announced the execution of an Agreement and Plan of Merger to acquire Celgene Corporation. This strategic move aims to significantly expand BMY's oncology and immunology portfolios. The filing also includes an investor presentation offering additional details on the proposed merger. Investors should note the cautionary statements regarding forward-looking information and the potential risks and uncertainties associated with the acquisition, including regulatory approvals, integration challenges, and market reception. The company urges investors to read the upcoming joint proxy statement/prospectus carefully for detailed information.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) announced its Earnings Per Share (EPS) guidance for the fiscal year 2019.
  • 2BMY entered into an Agreement and Plan of Merger to acquire Celgene Corporation.
  • 3The acquisition is expected to significantly enhance BMY's presence in oncology and immunology therapeutic areas.
  • 4An investor presentation providing further details on the proposed merger is included as an exhibit.
  • 5The filing emphasizes the importance of reviewing upcoming SEC filings, including a joint proxy statement/prospectus, for comprehensive details on the transaction.
  • 6Significant cautionary statements regarding forward-looking statements and potential risks and uncertainties associated with the merger are provided.

Frequently Asked Questions

The most significant news is Bristol-Myers Squibb's announcement of its agreement to acquire Celgene Corporation. The filing also includes the company's EPS guidance for 2019.

While not explicitly detailed in the 8-K, the acquisition is understood to be aimed at significantly strengthening Bristol-Myers Squibb's position in key therapeutic areas, particularly oncology and immunology, by integrating Celgene's robust pipeline and product portfolio.

The filing highlights several risks, including the potential for regulatory hurdles or delays in obtaining necessary approvals, challenges in integrating Celgene's business operations, potential disruption to business relationships, adverse effects on stock price, and the possibility of not achieving expected synergies and value creation.

Investors are urged to read the upcoming joint proxy statement/prospectus that Bristol-Myers Squibb and Celgene will file with the SEC. This document, along with other filings, will be available on the SEC's website and the companies' investor relations pages.